Novartis AG — COSENTYX (secukinumab)- (SUNSHINE) · Hidradenitis suppurativa (HS).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (9/26/25) through T+5. Run-up high $168.62 on 2/27/26, low $121.8 on 11/5/25 (T-120 to T-1). FDA decision 3/13/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-03-13
OutcomeApproved
Drug / candidateCOSENTYX (secukinumab)- (SUNSHINE)